Neuland Laboratories Limited announced the approval of its Unaudited Financial Results for the quarter and nine months ended December 31, 2025. The Board of Directors met on February 9, 2026, to confirm these figures, which include both Standalone and Consolidated statements. The company’s total consolidated revenue for the nine months reached ₹1,26,444.31 lakhs. Segment reporting details indicate that Europe remains a major contributor to revenue.
Neuland Laboratories Q3 FY2026 Financial Disclosure
Neuland Laboratories Limited has finalized and approved its Unaudited Financial Results for the third quarter and the nine months concluded on December 31, 2025. This information was shared following a Board of Directors meeting held on February 9, 2026.
Consolidated Performance Highlights (Nine Months Ended Dec 31, 2025)
The consolidated results show significant operational scale. Total consolidated income for the nine months was ₹1,26,444.31 lakhs, compared to ₹1,16,152.23 lakhs in the previous corresponding period. Total consolidated expenses amounted to ₹1,06,296.08 lakhs for the nine months.
Key profit figures for the nine months ended December 31, 2025 (Consolidated):
- Profit Before Tax: ₹20,148.23 lakhs
- Profit For The Period/Year: ₹15,132.58 lakhs
- Total Comprehensive Income: ₹15,115.33 lakhs
Quarterly Performance Snapshot (Q3 FY2026)
For the quarter ended December 31, 2025 (Consolidated):
- Revenue from Operations: ₹43,970.93 lakhs
- Profit Before Tax: ₹5,447.54 lakhs
The Earnings Per Share (EPS) for the quarter was reported at ₹31.50 (Basic and Diluted), which has not been annualised.
Consolidated Segment Reporting Analysis
The management classifies the Group’s operations into one primary reportable segment: ‘manufacture of active pharmaceutical ingredients and allied services’. However, geographical revenue details were provided:
| Segment Revenue | Q3 FY2026 (₹ Lakhs) | Nine Months FY2026 (₹ Lakhs) |
|---|---|---|
| India | 9,159.00 | 36,258.73 |
| Europe | 12,198.98 | 37,883.13 |
| USA and North America | 19,180.36 | 39,978.66 |
Non-current assets, as at December 31, 2025, are heavily weighted towards the India segment, totaling ₹1,33,319.64 lakhs.
Standalone Financial Overview
The Standalone Statement of Financial Results for the nine months ended December 31, 2025 shows Total Income at ₹1,26,444.21 lakhs, leading to a Profit For The Period/Year of ₹15,058.19 lakhs.
A notable exceptional item of ₹7,640.36 lakhs, resulting from the perpetual lease transfer of an investment property in the previous year, was disclosed separately for both Standalone and Consolidated results.
Auditor Review Conclusion
The review reports from MSKA & Associates LLP (for Consolidated results) and MSKA & Associates LLP (for Standalone results) concluded that nothing has come to their attention to indicate that the accompanying statements contain any material misstatement, based on their review procedures.
Source: BSE
